Atossa Therapeutics Releases Updated Corporate Presentation

What Happened Atossa Therapeutics, Inc. (ATOS) filed a Current Report on Form 8-K dated September 18, 2026, to disclose that it has made an updated corporate presentation available to the public. The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is attached to the filing.

Key Details

• Filing date: September 18, 2026 (Form 8-K under Item 7.01).
• Exhibit included: Exhibit 99.1 — Corporate Presentation dated September 18, 2026.
• Administrative exhibit: Exhibit 104 — Cover page interactive data file (Inline XBRL).
• The 8-K furnishes the presentation under Regulation FD; it does not report quarterly earnings, executive changes, or other financial results.

Why It Matters This filing makes Atossa’s latest investor-facing materials and corporate messaging available for review. For retail investors, the presentation may contain updated strategic, clinical development, or pipeline summaries that help assess the company’s current narrative and progress. Because the disclosure was made under Regulation FD, the company is publicly sharing the same information with the market; investors should review Exhibit 99.1 for any updates that could affect their view of ATOS.